Background: We conducted a phase 1 trial to determine the maximum tolerated dose (MTD), toxicity profile, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary activity of cabozantinib in children with refractory or relapsed solid tumors.
INTRODUCTION
Cabozantinib (XL184, COMETRIQ; CABOMETYX, Exelixis, San Francisco, CA) is a small molecule inhibitor of multiple tyrosine kinases including MET, VEGFR2, RET, and AXL. Selective inhibition of VEGFR2 may lead to increased invasiveness and metastasis, and preclinical models suggest that inhibition of VEGFR2 together with c-MET may decrease tumor size, decrease invasiveness and metastases. 1, 2 Cabozantinib, 140 mg capsules once daily, was FDA approved in In 2016, cabozantinib, 60 mg tablet once daily, was approved for adults with advanced renal cell carcinoma following prior antiangiogenic therapy. [3] [4] [5] The most commonly reported adverse drug reactions (≥25%) in adult trials were diarrhea, stomatitis, palmar-plantar erythrodysesthesia (PPE) syndrome, decreased weight, decreased appetite, nausea, vomiting, fatigue, oral pain, hair color changes, dysgeusia, hypertension, abdominal pain, and constipation. 3, 4 The approved dose of cabozantinib for adults with MTC is 140 mg/d (capsules); however, in the trial that lead to approval, 79% and 41% of patients had dose reductions to 100 mg/d and 60 mg/d, respectively. Adverse events (AEs) led to discontinuation in 16% of patients. 4 There is an ongoing trial to fulfill a post-marketing requirement to evaluate two different dosing regimens of cabozantinib in adult patients with MTC, 140 mg capsules and 60 mg tablets (NCT01896479). 6, 7 Cabozantinib is being evaluated in adults with prostate, genitourinary, colon, non-small cell lung, breast, hepatocellular carcinoma, sarcoma, and AML.
The primary objectives of this phase I trial were to identify a maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D), characterize the toxicity profile, and describe the pharmacokinetics (PK) of cabozantinib in pediatric patients with refractory or recurrent solid tumors. Additional objectives were to describe preliminary evidence of activity and pharmacodynamics (PD) of cabozantinib in this patient population.
PATIENTS AND METHODS

Patient eligibility
Eligible patients were between the ages of 2 and 18 years (y), had a body surface area ≥ 0.35 m 2 ; had a relapsed or refractory solid tumor including CNS tumors (Part A), or MTC (Part B); measurable or evaluable disease; no known curative therapy or therapy proven to prolong survival with an acceptable quality of life; a Lansky (≤16 y) or Karnofsky (> 16 y) performance status ≥ 50%; and were recovered from the acute toxic effects of prior anticancer therapy. In addition, they were able to swallow intact tablets, had adequate organ function defined as: absolute neutrophil count (ANC) ≥ 1000/mm 3 , platelet count ≥ 100,000/mm 3 , creatinine clearance or radioisotope GFR ≥ 70 ml/min/1.73 m 2 or serum creatinine(Cr; mg/dl) based on age and gender; urine protein ≤ 30 mg/dl in urinalysis or ≤1+ on dipstick; total bilirubin ≤ 1.5 × upper limit of normal (ULN) for age, ALT ≤ 110 U/l, serum albumin ≥ 2.8 g/dL; PT and INR ≤ 1.5 × ULN; serum amylase and lipase ≤ 1.5 × ULN; blood pressure ≤ 95th percentile for age, height, and gender, and were not receiving medication for treatment of hypertension.
Patients were not eligible if they had a history of congenital prolonged QTc syndrome, QTc > 480 msec; significant cardiac arrhythmias, stroke, or myocardial infarction within 6 months prior to enrollment; were receiving potent CYP3A4 inducers or inhibitors, systemic treatment anticoagulation, enzyme-inducing anticonvulsants, escalating doses of corticosteroids, or drugs that prolong QTc; or had any active bleeding or major surgical procedure within 28 days of enrollment or minor procedures within 7 days of enrollment.
This multi-institutional trial was conducted at Children's Oncology Group (COG) Phase I Consortium Institutions and approved by local IRBs. Informed consent, and assent as appropriate, was obtained from patients and their guardians prior to enrollment. The trial is listed on clinicaltrials.gov as NCT01709435. 6 
Treatment regimen and dose escalation
Cabozantinib (20 and 60 mg tablets supplied by Exelixis and distributed by the National Cancer Institute's Division of Cancer Treatment and Diagnosis) was administered orally in a fasted state (2 hr after or 1 hr before food) to achieve a weekly cumulative dose on a continuous dosing schedule in 28 day cycles. Due to limitations of available tablet strengths, dosing was based on a nomogram to achieve a total weekly dose within 10% of the intended dose (Supplementary Table   S1 ). Three dose levels were evaluated: 30, 40, and 55 mg/m 2 /day (d).
The trial was conducted in several parts: in Part A, the starting dose Subsequent cycles were administered if the patient met eligibility laboratory parameters, did not experience study-drug related adverse events (AEs) warranting discontinuation, and had no evidence of disease progression.
Radiographic disease evaluation was conducted at baseline, at the end of C1, C3, C5, and then every three cycles. Radiographic response was assessed using RECIST v 1.1 by the treating physician investigator.
In addition, objective responses or prolonged stable disease, defined as ≥6 cycles, were centrally reviewed by an independent radiologist.
Definition of dose-limiting toxicity
Hematologic dose-limiting toxicity (DLT) was defined as Grade 4 decrease in ANC or platelet count, any myelosuppression that caused a delay of >14 days between treatment cycles and, for patients with CNS tumors, more than one platelet transfusion administered for a platelet count ≤50,000/ l during a cycle.
Non-hematologic DLT was defined as any Grade 3 or 4 nonhematological toxicity with the exception of Grade 4 fever and the following Grade 3 toxicities: nausea and vomiting of <3 days duration, diarrhea ≤3 days duration, liver enzyme elevation that returned to eligibility or baseline levels within 7 days of drug interruption and did not recur upon re-challenge, electrolyte abnormality responsive to supplementation, asymptomatic amylase or lipase elevation that resolved to ≤Grade 1 within 7 days of drug interruption and did not recur upon re-challenge, fever, infection <5 days duration, and proteinuria unless it was confirmed with a second measurement within 72 hr. In patients who began antihypertensive therapy, a blood pressure > 10 mm Hg but ≤25 mm Hg above the 95th percentile for age, height, and gender for >14 days was a DLT. In addition, any Grade 2 non-hematological toxicity that persisted for ≥7 days and was considered sufficiently medically significant or intolerable by patients that it required treatment interruption, and any toxicity requiring interruption of study drug during a cycle of therapy for ≥7 days or which recurs upon drug challenge was considered a DLT.
Definition of maximum tolerated dose (MTD) and dose modifications for toxicity
The MTD, determined from toxicity during C1, was defined as the dose level immediately below the level in which two or more in a cohort of six patients experienced a DLT. Two dose reductions were permitted following recovery from a DLT.
Pharmacokinetics
Plasma pharmacokinetic sampling was performed at the beginning of C1 and at steady state. Samples were obtained on all patients prior to and 4 hr after the dose on Cycle 1 Day 1 (C1D1), prior to and 2, 4, 8, and 24 hr after the dose on C1D21, and prior to the dose on C3D1. Plasma concentrations of cabozantinib were measured using a validated, previously described, LC-MS/MS method. 9 Pharmacokinetic parameters were calculated by standard non-compartmental analysis using Phoenix WINNONLIN 6.3 (Certara, L.P., St. Louis, MO).
Pharmacodynamics
Blood samples for biomarker analysis for known targets of cabozantinib and markers of hypoxia, inflammation, and angiogenesis were collected at baseline and prior to cabozantinib dosing on C1D1, C1D21, and C1D28. Plasma (EDTA) samples were shipped on dry ice to AssayGate (Ijamsville, MD) for multiplex immunoassay using standard protocols for quantitation of soluble forms of c-MET, VEGFR2, HGF, AXL, CA9, EPO, OPN, PIGF, IL-6, and TIMP-1. Analyte concentrations in samples were determined by either four-or five-parameter logistic regression algorithm with analysis of the median fluorescence intensity or optical density readings of each eight-point standard curve.
RESULTS
Patient characteristics
Forty-one patients were enrolled; all were eligible and 36 were evaluable for the primary endpoints. The five inevaluable patients either did not receive at least 85% of protocol-prescribed drug during C1 as a result of early disease progression (n = 4) or withdrew consent for nontoxicity reasons (n = 1). Patient demographics and disease characteristics are presented in Table 1 . The median (range) number of cycles administered was 3 . At the time of data cut-off, four patients continued on protocol therapy, two patients in C13 (ependymoma and Ewing sarcoma), and two patients with MTC, one in C20, and one in C25.
Toxicity and MTD
Six patients were enrolled at 30 mg/m 2 /d. No C1 DLTs were observed.
Twenty-three patients were enrolled at 40 mg/m 2 /d (9 in Part A, 4 in Part B, and 10 in the PK cohort). Nineteen patients were evaluable for toxicity; five patients (26%) had a DLT during C1 (PPE; mucositis and PPE; and increased ALT, lipase, and bilirubin).
Twelve patients were enrolled at 55 mg/m 2 /d (six in Part A and six in the PK expansion cohort). Eleven were evaluable for toxicity; three patients (27%) had a C1 DLT (headache and fatigue in one patient, RPLS and hypertension in another patient, and proteinuria and hypertension in the third patient). Table 2 Hematologic and non-hematologic adverse events as well as laboratory abnormalities that were assessed by the investigator to be at least possibly attributed to cabozantinib are summarized in Supplementary Table S2 . Hypertension, gastrointestinal disorders (diarrhea, nausea, and vomiting), constitutional (fatigue, arthralgia, weight loss), dermatological (rash and hypopigmentation of hair), and laboratory abnormalities (increased hepatic transaminases, hypothyroidism, proteinuria) were prevalent. All of these toxicities were Grade 1 or 2 except for cases of Grade 3 hypertension (n = 3), PPE (n = 3), diarrhea (n = 2), increased ALT (n = 2), proteinuria (n = 1), fatigue (n = 1), and weight loss (n = 1). Overall, the toxicity profile was similar to adults.
Twenty-six patients underwent growth plate evaluations. Growth plate widening on therapy ( 
Pharmacokinetics
Steady-state pharmacokinetics (day 22) were evaluated in 32 patients.
Estimates of the cabozantinib pharmacokinetic parameters are summarized in Table 3 . The median time of the peak concentration was 2 hr after drug administration. Mean peak concentrations were greater than 1693 ng/ml, and similar across the dose levels studied. Cabozan- 
Pharmacodynamics
Change from baseline in plasma pharmacodynamic markers is presented in Table 4 . AXL, CA9, and PIGF increased on study D21 and D28 versus baseline. OPN, TIMP-1, and VEGFR2 decreased on D21
and D28 versus baseline. The Wilcoxon signed rank test was used to test the null hypothesis that there was no change in biomarkers at D21
and D28 versus baseline (P-values were adjusted for multiple hypothesis testing using the Bonferroni correction). There were significant changes in AXL, CA9, OPN, PIGF, TIMP-1, and VEGFR2 (P < 0.05) at both D21 and D28 versus baseline. There was no significant change in cMET, EPO, HGF, or IL-6. There was no significant biomarker change a Average daily dose for each patient over all cycles was calculated as total dose in milligrams received per cycle divided by body surface area and cycle length. b Three patients had one dose reduction, two patients had two dose reductions. c Two patients had one dose reduction, two patients had two dose reductions. DLT, dose-limiting toxicity; SD, standard deviation. 
TA B L E 2 Incidence of dose-limiting toxicities and dose modifications
Response
There were no complete responses. Four patients had a partial response (PR), and seven patients had prolonged stable disease (SD). 
Calcitonin and CEA
Five patients with advanced MTC were treated on the trial. All had multiple endocrine neoplasia type 2B (MEN2B), a genetic cancer predisposition syndrome caused by germline activating mutations in the RET proto-oncogene. All had a point mutation in exon 16 (codon 918).
A decrease in calcitonin from baseline to the end of C1, ranging from 24% to 87%, was observed. Changes in CEA were more variable with three patients having a decrease and two patients, who remained on trial for 20 and 2 cycles respectively, with an increase from baseline to post C1.
DISCUSSION
No protocol-defined MTD was reached in this dose-escalation phase Patients in this trial received a median of three cycles (range 1-25). DLTs after C1 occurred at all dose levels. To further evaluate the toxicity profile across dose levels, the average daily dose actually received was calculated for each patient and then averaged for each dose level (Table 2 ). This average daily dose was the sum of all course doses divided by the cycle length. This Table S1 ). In addition, these factors limited the ability for precise dose reductions.
TA B L E 3 Plasma pharmacokinetic parameters
Cabozantinib capsules (140 mg) are FDA approved in adults with MTC. In adults with renal cell carcinoma, cabozantinib tablets (60 mg)
are FDA approved. These formulations are not bioequivalent. The tablet formulation was used in this pediatric study and the apparent clearance (1.1-1.8 l/hr/m 2 ) in children was variable but similar to reported clearance of this formulation in healthy adults (1.3-2 l/hr/m 2 ). 10 The toxicity profile of cabozantinib in pediatric patients was similar to that seen in adults. 5 Common toxicities included increased ALT, diarrhea, fatigue, proteinuria, hypothyroidism, hypertension, weight loss, PPE, anorexia, and nausea. These toxicities were generally low grade and manageable with supportive care, dose interruption, or reduction. 
